Journal Reviews
Ranibizumab for the treatment of age-related macular degeneration
This multicentre randomised prospective open label study compared 0.5 versus 2mg of ranibizumab in patients with submacular retinal pigment epithelial (RPE) detachment due to age-related macular degeneration. Four treatment regimens were used for the two strengths either monthly for 12...
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
Three years of experience with quantiferon-TB Gold Testing in patients with uveitis
Quantiferon-TB Gold is a new alternative to the tuberculin skin test that utilises synthetic peptides representing M. tuberculosis antigens ESAT-6, CFP-10, TB7.7 and upon incubation with whole blood IFN-γ is released from pre-sensitised T cells and can be measured by...
Aqueous humour cytokine levels in PCV and nAMD
This study looks into the possible roles of various cytokines or growth factors in the pathogenesis of exudative age-related macular degeneration (AMD) by comparing aqueous levels of 14 cytokines between eyes with polypoidal choroidal vasculopathy (PCV) and those with neovascular...
Intravitreal ranibizumab for the treatment of myopic CNV
The authors conducted a prospective study. Sixty-four patients (65 eyes) attended the 12-month follow-up examination. The mean patient age was 47.8 years. Fifty-five patients (86.0%) were females. All patients had pathologic myopia (a spherical equivalent of more than − 6.0...
Hyper reflective foci (HRF) on OCT in diabetic retinopathy
This study investigated the presence of hyper reflective foci (HRF) in asymptomatic patients affected by type 1 or type 2 diabetes, separately, without clinically significant diabetic macular oedema and visual impairment. In total 71 eyes with non-proliferative diabetic retinopathy were...
VEGF and axial length (RVU)
The authors of this paper set out to examine whether the concentrations of VEGF in the vitreous were associated with refractive error and axial length in eyes without retinal disease, except of macular holes or epiretinal membranes. A vitreous sample...
Intravitreal injection related endophthalmitis
This article reviews the incidence, clinical findings, risk factors, management and visual outcomes in intravitreal injection related endophthalmitis. Incidence of this complication is reported to be in the range of 0.038% to 0.065% (1 in 2000-3000 injections). Patients present typically...
Methotrexate and mycophenolate mofetil for non-infectious uveitis
This is the first reported randomised clinical trial comparing methotrexate versus mycophenolate mofetil (MMF) for the treatment of non-infectious intermediate uveitis, posterior uveitis or panuveitis. To be eligible for recruitment, patients had to be on ≥15mg oral prednisone and demonstrated...
Timing of vitrectomy for retained lens fragments
The purpose of this study was to compare the results of same setting vitrectomy with delayed vitrectomy for retained lens fragments following cataract surgery. Same setting vitrectomy was defined as the patient not leaving the operating table following cataract surgery....
Medical management and diabetic retinopathy progression
The ACCORD Eye Study was designed to evaluate the benefit of intensive glycaemic control (HbA1c <6.0% vs 7.0-7.9%), intensive systolic blood pressure control (<120mmHg vs. <140mmHg), and combined fenofibrate and simvastatin therapy in the development and progression of diabetic retinopathy....
Prognostic information for PRP-naive patients
The Diabetic Retinopathy Study group demonstrated that pan retinal laser photocoagulation (PRP) reduces severe vision loss by up to 50% in cases of proliferative diabetic retinopathy (PDR). The authors of this current study aimed to provide information for laser naive...
